Piper Sandler analyst Matt O’Brien raised the firm’s price target on Integer (ITGR) to $140 from $125 and keeps an Overweight rating on the shares. The firm recommends buying the shares on yesterday’s post-earnings selloff. Contract manufacturer results can be volatile, which is likely what happened in the Cardio and Vascular business this quarter, the analyst tells investors in a research note. The firm suspects the unit will lift in the back half of the year through improved growth.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITGR:
- Integer Holdings Announces Leadership Changes and Strong Q3 Results
- Integer names Payman Khales COO, Andrew Senn president, Cardio & Vascular
- Integer reports Q3 adjusted EPS $1.43, consensus $1.36
- Integer raises sees FY24 adjusted EPS $5.24-$5.43, consensus $5.30
- Integer Holdings (ITGR) Q3 Earnings Cheat Sheet